Physician profile
Lindsay E Smith
NPI 1508029620
$2,065.39
in general payments reported to CMS, 2019-2025
25 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.03 · 2021: $204 · 2022: $219 · 2023: $298 · 2024: $767 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $203.95 | 2022-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $192.18 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $128.03 | 2022-2025 | Veozah |
| Abbvie INC. | $121.67 | 2023-2025 | Linzess, Viberzi |
| Optinose US, INC. | $121.18 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $120.39 | 2024 | Zeposia |
| Pfizer INC. | $92.74 | 2023-2024 | |
| Genzyme Corporation | $90.08 | 2024 | |
| Glaxosmithkline, LLC. | $74.74 | 2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $62.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Qol Medical, LLC | $56.55 | 2021 | |
| Janssen Biotech, INC. | $43.73 | 2025 | Stelara, Tremfya, Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.26 | 2023-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $29.07 | 2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26.86 | 2025 | |
| Janssen Pharmaceuticals, INC | $26.43 | 2021 | |
| Inspire Medical Systems, INC. | $24.33 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $22.21 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.42 | 2024 | Caplyta |
| Celgene Corporation | $19.13 | 2022 | |
| Vifor Pharma, INC. | $19.03 | 2019 | |
| Intercept Pharmaceuticals, INC. | $17.91 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.25 | 2023 | Xifaxan |
| Mylan Specialty L.P. | $13.95 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.